The incidence of translocation t(11;14) among patients with multiple myeloma in a single clinic.

Scott JewMarissa-Skye GoldwaterSean BujarskiBernard RegidorMarsiye Emamy-SadrRegina SwiftBenjamin EadesJonathan SaidJames R Berenson

Published in: American journal of clinical pathology (2023)

This report suggests that some patients may need to retest for this genetic aberration due to the possibility of false negatives and the potential benefit of identifying the t(11;14) marker for patients who may be candidates for a highly effective targeted therapy consisting of the BCL-2 inhibitor venetoclax.

Keyphrases

end stage renal disease
multiple myeloma
ejection fraction
newly diagnosed
peritoneal dialysis
primary care
gene expression
risk assessment
copy number
climate change
human health
patient reported
chronic lymphocytic leukemia